NanobiotixNBTX +3.18%24 Net Margin % is -394.02% as of Dec. 2025. GuruFocus rates NBTX with a GF Score™ of 24/100. The stock has 3 warning signs investors should review. Among 947 Biotechnology companies, Nanobiotix ranks better than 50.69% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Nanobiotix's Net Income for the
six
months ended in Dec. 2025 was $-21.75 Mil. Nanobiotix's Revenue for the
six
months ended in Dec. 2025 was $5.52 Mil. Therefore, Nanobiotix's net margin for the quarter that ended in Dec. 2025 was -394.02%.
The historical rank and industry rank for Nanobiotix's Net Margin % or its related term are showing as below:
NBTX'
s Net Margin % Range Over the Past 10 Years
Min: -470030 Med: -10374.21 Max: 586.84
Current: -80.83
NBTX's Net Margin % is ranked better than 50.69% of 947
companies
in the Biotechnology industry
Industry Median: -89.33
vs NBTX: -80.83
Nanobiotix (NAS:NBTX) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Nanobiotix Net Margin % Related Terms
Nanobiotix Net Margin % Historical Data
* Premium members only.
The historical data trend for Nanobiotix's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Nanobiotix's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanobiotix Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nanobiotix's Net Margin % distribution charts can be found below:
* The bar in red indicates where Nanobiotix's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanobiotix (NBTX) has a Net Margin % of -394.02% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Nanobiotix and its competitors. According to the industry distribution chart, Nanobiotix ranks #467 out of 947 companies in the Biotechnology industry, placing it in the top 49.3%.
Is Nanobiotix's Net Margin % too high?
Nanobiotix's current Net Margin % is -394.02%. Based on the distribution chart, Nanobiotix ranks #467 out of 947 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Nanobiotix has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Nanobiotix's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanobiotix ranks #467 out of 947 companies for Net Margin %. This puts Nanobiotix in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Nanobiotix and its competitors. Nanobiotix's current Net Margin % is -394.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanobiotix stock overvalued right now?
Nanobiotix (NBTX) has a current Net Margin % of -394.02%. The current Net Margin % is -394.02%. Nanobiotix's overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Nanobiotix (NBTX), the current Net Margin % is -394.02% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.
24GF Score
Get the complete analysis for NBTX
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NBTX has been successfully added to your 
